Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New nasal spray to treat pain in cancer patients

  • Comment

An intranasal fentanyl spray (Instanyl) has been launched for the treatment of breakthrough pain experienced by patients with cancer.

The spray can be used by patients who are already taking maintenance opioid therapy for chronic cancer pain.

Maintenance therapy is defined as at least:

  • 60 mg of oral morphine daily,
  • 25 micrograms of transdermal fentanyl per hour,
  • 30 mg oxycodone daily,
  • 8 mg of oral hydromorphone daily
  • or an equilivent dose of another opioid for a week or longer.

Click here for a summary of product characteristics.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs